Use of minimal residue disease as an endpoint in chronic lymphocytic leukaemia studies

  • Email
  • Help
Current effective version

Draft guideline

Reference numberEMA/629967/2014
Published15/12/2014
Effective from 
KeywordsMinimal residual disease (MRD), chronic lymphocytic leukaemia (CLL)
DescriptionThis document describes the basis and regulatory requirements for the use of minimal residue disease as an intermediate endpoint to predict clinical benefit in trials in chronic lymphocytic leukaemia.


Document history

First version

Current version

Overview of comments

 

Draft guideline

Published: 15/02/2016

 

Published: 15/12/2014

How helpful is this page?

Average rating:

 Based on 0 ratings

Add your rating:

See all ratings
0 ratings
0 ratings
0 ratings
0 ratings
0 ratings
    

Tell us more